FDA Weighs Next Move After Appellate Court Rebuffs Patent Delisting Policy
Executive Summary
FDA is assessing its next step following an appeals court ruling confirming that the agency's position on delisting patents is inconsistent with Hatch/Waxman
You may also be interested in...
Teva Asks FDA To Relist Risperdal Patent And Restore 180-Day Exclusivity
J&J's delisted Risperdal patent should be returned to the "Orange Book" and 180-day exclusivity restored to Teva Pharmaceuticals, the generic company states in a petition to FDA
Teva Asks FDA To Relist Risperdal Patent And Restore 180-Day Exclusivity
J&J's delisted Risperdal patent should be returned to the "Orange Book" and 180-day exclusivity restored to Teva Pharmaceuticals, the generic company states in a petition to FDA
Zocor Exclusivity: Ranbaxy Needs Quick Win In Suit Seeking Patent Re-Listing
Ranbaxy needs a relatively quick win in its lawsuit against FDA if it hopes to benefit from the 180-day exclusivity it is claiming for Zocor 80 mg